Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

AbbVie’s Parkinson’s disease therapy recommended by NICE for advanced disease

Around 900 adults with advanced Parkinson’s are set to benefit from Produodopa

EU flag

EMA announces latest action to address critical medicine shortages in EU

The documents will support Member States to collaboratively address shortages

Biogen Idec building

Biogen/Eisai’s Alzheimer’s disease drug shows promise as subcutaneous formulation

Eisai said it aims to apply for US approval of SC Leqembi by the end of March 2024

- PMLiVE

ICR experts develop clinical trial guidelines to support future research

The new guidance documents are expected to transform dose-finding trials

- PMLiVE

Coming of age

People are investing in longevity… and by ‘people’, I mean profit-seekers

- PMLiVE

FDA approves Servier’s Tibsovo as first targeted therapy for rare blood cancer

Approximately 16,000 people in the US are diagnosed with myelodysplastic syndromes every year

- PMLiVE

GSK’s RSV vaccine Arexvy shows promise in adults aged 50 to 59 years

Arexvy has already been approved in the US and Europe to protect those aged 60 years and older

- PMLiVE

Innovative Trials and Avillion announce free webinar on solving patient recruitment and retention challenges

Register now for the free live webinar on 15 November 2023 at 3pm GMT

- PMLiVE

Almirall launches call for proposals to better understand skin diseases

AlmirallShare has received around 600 proposals spanning 60 countries since 2017

- PMLiVE

UCL study finds use of existing drugs improves cervical cancer outcomes

The approach was shown to reduce the risk of death or cancer recurrence by 35%

- PMLiVE

Fertility awareness: empowering men to discuss male infertility

By Jamie Austin

- PMLiVE

Neuromyelitis optica spectrum disorder: is there hope on the horizon?

The new science behind the management of this devastating rare autoimmune disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links